Targeting Cancer Lysosomes with Good Old Cationic Amphiphilic Drugs
Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Forskning › fagfællebedømt
Standard
Targeting Cancer Lysosomes with Good Old Cationic Amphiphilic Drugs. / Ellegaard, Anne Marie; Bach, Peter; Jäättelä, Marja.
Organelles in Disease . Bind 185 Springer, 2023. s. 107-152 (Reviews of Physiology, Biochemistry and Pharmacology, Bind 185).Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - CHAP
T1 - Targeting Cancer Lysosomes with Good Old Cationic Amphiphilic Drugs
AU - Ellegaard, Anne Marie
AU - Bach, Peter
AU - Jäättelä, Marja
N1 - Publisher Copyright: © 2020. Springer Nature Switzerland AG.
PY - 2023
Y1 - 2023
N2 - Being originally discovered as cellular recycling bins, lysosomes are today recognized as versatile signaling organelles that control a wide range of cellular functions that are essential not only for the well-being of normal cells but also for malignant transformation and cancer progression. In addition to their core functions in waste disposal and recycling of macromolecules and energy, lysosomes serve as an indispensable support system for malignant phenotype by promoting cell growth, cytoprotective autophagy, drug resistance, pH homeostasis, invasion, metastasis, and genomic integrity. On the other hand, malignant transformation reduces the stability of lysosomal membranes rendering cancer cells sensitive to lysosome-dependent cell death. Notably, many clinically approved cationic amphiphilic drugs widely used for the treatment of other diseases accumulate in lysosomes, interfere with their cancer-promoting and cancer-supporting functions and destabilize their membranes thereby opening intriguing possibilities for cancer therapy. Here, we review the emerging evidence that supports the supplementation of current cancer therapies with lysosome-targeting cationic amphiphilic drugs.
AB - Being originally discovered as cellular recycling bins, lysosomes are today recognized as versatile signaling organelles that control a wide range of cellular functions that are essential not only for the well-being of normal cells but also for malignant transformation and cancer progression. In addition to their core functions in waste disposal and recycling of macromolecules and energy, lysosomes serve as an indispensable support system for malignant phenotype by promoting cell growth, cytoprotective autophagy, drug resistance, pH homeostasis, invasion, metastasis, and genomic integrity. On the other hand, malignant transformation reduces the stability of lysosomal membranes rendering cancer cells sensitive to lysosome-dependent cell death. Notably, many clinically approved cationic amphiphilic drugs widely used for the treatment of other diseases accumulate in lysosomes, interfere with their cancer-promoting and cancer-supporting functions and destabilize their membranes thereby opening intriguing possibilities for cancer therapy. Here, we review the emerging evidence that supports the supplementation of current cancer therapies with lysosome-targeting cationic amphiphilic drugs.
KW - Cancer
KW - Cathepsins
KW - Cationic amphiphilic drugs
KW - Cell death
KW - Lysosome
KW - pH
KW - SMPD1
U2 - 10.1007/112_2020_56
DO - 10.1007/112_2020_56
M3 - Book chapter
C2 - 33398504
AN - SCOPUS:85147092737
SN - 978-3-031-22594-9
VL - 185
T3 - Reviews of Physiology, Biochemistry and Pharmacology
SP - 107
EP - 152
BT - Organelles in Disease
PB - Springer
ER -
ID: 337596238